Gemcitabine (NCT04891289)

Name: Gemcitabine trial for Intrahepatic Cholangiocarcinoma (NCT04891289)
Uploaded: 2026-10-31T16:04:16.421Z
Duration: 1 min 22 s
Description: Gemcitabine trial for Intrahepatic Cholangiocarcinoma (NCT04891289). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04891289.

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery: a one-minute explainerNCT048912891 min

Gemcitabine trial for Intrahepatic Cholangiocarcinoma (NCT04891289). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated, unresectable intrahepatic cholangiocarcinoma confined to the liver, with an exception for removable regional lymph nodes. Patients must be fit for pump-placement surgery.

The idea: compare intravenous gemcitabine and oxaliplatin alone against the same chemotherapy plus a liver-artery pump delivering floxuridine and dexamethasone. Floxuridine disrupts DNA synthesis. Crossover is allowed after liver-only progression, not progression elsewhere.

This phase 2 study plans 164 patients. Andrea Cercek leads at Memorial Sloan Kettering in New York. Seven US locations are marked recruiting; six provide only limited protocol activities.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.